EGFR TKI combination with immunotherapy in non-small cell lung cancer
Year: 2017
Type: review
Source: Expert Opinion on Drug Safety
Institutions: Samsung Medical Center, Sungkyunkwan University
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Keywords: EGFR tyrosine kinase inhibitors, immunotherapy, non-small cell lung cancer, anti-PD-1 therapy, acquired drug resistance, EGFR mutation, nivolumab, erlotinib, osimertinib, durvalumab, gefitinib, atezolizumab, interstitial lung disease, elevated liver enzymes, treatment-related adverse events
Open Access status: closed
OpenAlex ID: W2593630992
